Zevra Therapeutics (ZVRA) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
8 Jun, 2026Mission and vision
Aims to redefine possibilities in rare disease therapeutics, focusing on patient-centric innovation and accountability.
Seeks to make a transformational impact through insights from patients and a culture of integrity and courage.
Portfolio and pipeline
Offers commercial-stage rare disease products and late-stage clinical assets, including MIPLYFFA for NPC and OLPRUVA for UCD.
Arimoclomol (MIPLYFFA) approved by FDA in 2024 for NPC, with EU MAA under review and IP protection through 2031.
Celiprolol in Phase 3 for VEDS, with orphan drug and breakthrough therapy designations.
Financial performance and position
Generated $106.5M net revenue in 2025 and exited Q1 2026 with $236.8M in cash, cash equivalents, and investments.
Q1 2026 net income was $37.9M, with no debt and strong operational discipline.
Revenue sources include product sales, expanded access reimbursements, and licensing/royalty income.
Latest events from Zevra Therapeutics
- Integrated commercial and clinical strategies are expanding rare disease market reach and pipeline.ZVRA
Canaccord Genuity's 46th Annual Growth Conference - Strong H1 2026 revenue and cash position support growth in rare disease therapeutics.ZVRACorporate presentation
- Q2 2026 revenue rose 53% to $39.7M, with $8.8M net income and $260.2M in cash reserves.ZVRAQ2 2026
- Accelerated commercial launch and strong payer engagement drive early success for new rare disease therapy.ZVRAGuggenheim Securities Inaugural Healthcare Innovation Conference
- AI-driven patient identification and global expansion fuel growth and pipeline acceleration.ZVRAH.C. Wainwright 4th Annual BioConnect Investor Conference
- Q1 2026 net income hit $37.9M, revenue rose 78%, and debt was eliminated.ZVRAQ1 2026
- Shareholders to vote on board declassification, director elections, and auditor ratification.ZVRAProxy filing
- Record revenue, foundational NPC therapy, and advancing VEDS pipeline fuel rare disease growth.ZVRACorporate presentation
- Miplyffa's U.S. launch and $150M PRV sale extend cash runway and support 2025 growth.ZVRAQ4 2024